Domestic pharmaceutical companies are stepping up efforts to develop the second Covid-19 therapy to win the regulator’s approval following Celltrion's Regkirona.Chong Kun Dang, GC Pharma, and Daewoong Pharmaceutical are closest to receive the next authorization. The three companies are also drawing
Hugel, a medical aesthetic company, said Tuesday that it recorded the highest sales amount ever in 2020 despite the Covid-19 pandemic, demonstrating the company’s growth potential.The company marked consolidated sales of 211 billion won ($198.1 million) last year, up 3.2 percent from 2019. Hugel als
The Seoul High Court has dismissed the health authorities’ appeal concerning the suspension of execution of the reduced insurance coverage for choline alfoscerate (CA) drugs and ruled that benefits remain until the merits of the civil case end.The Ministry of Health and Welfare had filed a complaint
Pfizer’s lung cancer drug lorlatinib (brand name in U.S.: Lorbrena) obtained the regulator’s nod for therapeutic purposes the most among experimental treatments in Korea in 2020, government data showed.The Ministry of Food and Drug Safety’s data, analyzed by Korea Biomedical Review, demonstrated tha
Yuhan's Leclaza (ingredient: lazertinib), Korea's 31st novel drug that treats lung cancer, has reached the commercialization stage, raising expectations for a new treatment option.The drug received approval from the Ministry of Food and Drug Safety on Jan. 18, on the condition that the company submi
Sanofi Pasteur Korea has voluntarily withdrawn its bid for supplying hepatitis A vaccines to the military, as the company failed to meet the qualification after winning it by offering about 20 percent lower price. The second-highest bidder is undergoing review for the public procurement after Sanofi
Daewoong Pharmaceutical said Friday its DWRX2003 (niclosamide), a Covid-19 treatment candidate, has been selected as a state-supported project in building production facilities. The company will receive 1.9 billion won ($1.7 million) from the Ministry of Health and Welfare.Niclosamide, which Daewoon
The drug regulator recently refused to approve a local trial of Nature Cell’s Covid-19 treatment candidate Astrostem-V. In response, Nature Cell said it would not seek the nod again in Korea but instead focus on the U.S. trial.In a public filing, Nature Cell said that the Ministry of Food and Drug S
Takeda’s Alunbrig (ingredient: brigatinib), a treatment for anaplastic lymphoma kinase(ALK)-positive non-small cell lung cancer (NSCLC), is likely to get health insurance benefits in the first-line therapy within the first half of this year and compete against Alecensa, sources said.On Jan. 27, the
Shareholders of Medytox have taken collective action to demand the company’s explanation regarding the revocation of the permit for Innotox, a botulinum toxin (BTX) product.They also warned that they could file a lawsuit to demand the dismissal of Medytox CEO Jung Hyun-ho.Law firm Oh Kims Law &Co. s
KB Pharm said it would cooperate with two Swiss partners to enter the U.S. and European antibiotic market.The drugmaker, an affiliate of Chong Kun Dang, has signed a CMO (contract manufacturing organization) deal with Basilea Pharmaceutica International, a multinational antibiotics developer, to sup
Hanmi Pharmaceutical said Thursday that its annual sales increased in 2020, but its operating and net profit declined due to the export drop caused by the Covid-19 and revoked technology transfer deal with Sanofi.The company’s operating profit plunged 53.1 percent to 48.7 billion won, from 103.9 bil
Korean pharmaceutical companies pulled the plug on more than 4,000 drugs last year to increase their profitability.The number of drugs withdrawn from the market has increased significantly since the government implemented an item renewal system in 2018, allowing pharmaceutical companies to throw out
Eisai’s Lenvima is threatening Bayer’s Nexavar, the No. 1 drug in the liver cancer treatment market. Lenvima’s outpatient prescriptions jumped 132 percent in 2020 compared to a year earlier, while those of Nexavar dropped 31 percent.U-BIST data, analyzed by Korea Biomedical Review, has shown that ou
Biopharmaceutical companies planning to make initial public offerings through the “special technology listing system” are on the strain after the Korea Exchange (KRX) drastically strengthened standards for such qualifications this year.Some are pushing ahead with their initial plans, but others have
The share prices of Hanall Biopharma, a subsidiary of Daewoong Pharmaceutical, plunged Tuesday after its global partner, Immunovant, suspended the phase 2 clinical trials of its eye disease drug candidate, IMVT-1401.The U.S. company said on Tuesday (local time) that it had observed physiological sig
Eli Lilly Korea's Taltz, an interleukin (IL)-17A inhibitor that recently began to receive insurance benefits, will become a new alternative for treating local ankylosing spondylitis patients, according to a researcher who conducted clinical trials with the drug."Only one in three local patients with
Korean pharmaceutical and biotech companies are rushing to develop a Covid-19 treatment using natural ingredients.They are aggressively conducting trials, particularly in India, because the country has many Covid-19 cases and high unmet clinical needs.Last year, India eased drug regulations on the n
Employees transferred from MSD Korea to its spinoff company Organon Korea said they would form a trade union to solidify job security.Han Il-ho, the leader in preparing a labor union at Organon Korea, said he submitted the application for establishing a union to the Seoul Regional Employment and Lab
Korean biopharmaceutical companies signed technology transfer deals worth more than 10 trillion won ($8.96 billion) last year. However, they saw nearly 80 percent of such deals go up in smoke due to the cancellation of contracts by multinational giants, industry sources said Tuesday.Global pharmaceu